RU2017145602A - Жидкие композиции целекоксиба для перорального введения - Google Patents

Жидкие композиции целекоксиба для перорального введения Download PDF

Info

Publication number
RU2017145602A
RU2017145602A RU2017145602A RU2017145602A RU2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A RU 2017145602 A RU2017145602 A RU 2017145602A
Authority
RU
Russia
Prior art keywords
weight
volume
pharmaceutical preparation
amount
preparation according
Prior art date
Application number
RU2017145602A
Other languages
English (en)
Russian (ru)
Other versions
RU2017145602A3 (enExample
Inventor
Джеффри Скотт КИЛ
Томас Джеффри БРАЙАНТ
Ришар Жерар ЛЕВАССЕР
Хью Грэг ТОМАС
Original Assignee
Кил Лэборетериз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кил Лэборетериз, Инк. filed Critical Кил Лэборетериз, Инк.
Publication of RU2017145602A publication Critical patent/RU2017145602A/ru
Publication of RU2017145602A3 publication Critical patent/RU2017145602A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
RU2017145602A 2015-05-29 2016-05-24 Жидкие композиции целекоксиба для перорального введения RU2017145602A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562168012P 2015-05-29 2015-05-29
US62/168,012 2015-05-29
US15/163,258 US20160346300A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration
US15/163,258 2016-05-24
PCT/US2016/033937 WO2016196085A1 (en) 2015-05-29 2016-05-24 Liquid formulations of celecoxib for oral administration

Publications (2)

Publication Number Publication Date
RU2017145602A true RU2017145602A (ru) 2019-07-02
RU2017145602A3 RU2017145602A3 (enExample) 2019-11-25

Family

ID=57396976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017145602A RU2017145602A (ru) 2015-05-29 2016-05-24 Жидкие композиции целекоксиба для перорального введения

Country Status (9)

Country Link
US (1) US20160346300A1 (enExample)
EP (1) EP3302430A4 (enExample)
JP (1) JP2018516279A (enExample)
AU (1) AU2016270504A1 (enExample)
BR (1) BR112017025527A2 (enExample)
CA (1) CA2987388A1 (enExample)
MX (1) MX2017015202A (enExample)
RU (1) RU2017145602A (enExample)
WO (1) WO2016196085A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605047B2 (ja) * 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド 疼痛治療のためのセレコキシブの経口用組成物
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof
CN115737554B (zh) * 2022-11-28 2024-07-09 宜昌人福药业有限责任公司 一种氯巴占口服混悬剂的制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib
US12678405B1 (en) 2025-07-29 2026-07-14 Codadose Incorporated Oral liquid compositions of celecoxib

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
IN191512B (enExample) * 2000-01-21 2003-12-06 Panacea Biotech
CA2406226A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20030157172A1 (en) * 2001-12-20 2003-08-21 Lu Guang Wei Pharmaceutical suspension for oral administration
ATE541562T1 (de) * 2002-06-17 2012-02-15 Taro Pharmaceuticals Usa Inc Ibuprofen-suspension
WO2004047752A2 (en) * 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110183944A1 (en) * 2010-01-28 2011-07-28 Paul Ashton SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS
EP3530268B1 (en) * 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutic treatment
CN103932977A (zh) * 2014-04-15 2014-07-23 江苏正大清江制药有限公司 一种塞来昔布制剂的制备方法

Also Published As

Publication number Publication date
RU2017145602A3 (enExample) 2019-11-25
CA2987388A1 (en) 2016-12-08
BR112017025527A2 (pt) 2018-08-07
EP3302430A4 (en) 2019-05-29
AU2016270504A1 (en) 2017-12-14
MX2017015202A (es) 2018-07-06
EP3302430A1 (en) 2018-04-11
JP2018516279A (ja) 2018-06-21
US20160346300A1 (en) 2016-12-01
WO2016196085A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
ES2211192T3 (es) Jarabe antihistaminico estabilizado que contiene acido aminopolicarboxilico como estabilizante.
KR101695580B1 (ko) 증가된 안정성의 신규한 액체 조성물
CA2567075A1 (en) Pharmaceutical suspension composition
US20130178476A1 (en) Methotrexate composition
KR20070024722A (ko) 저작에 대하여 안정적인 캡슐
JP2011506587A5 (enExample)
KR101947198B1 (ko) 수난용성 약물 함유 의약 조성물
US9474713B2 (en) Chewable composition for oral administration and process for preparing thereof
WO2005000279A1 (ja) 硬カプセル剤
US10596263B2 (en) Pazopanib formulation
US20160346300A1 (en) Liquid formulations of celecoxib for oral administration
JPWO2014002553A1 (ja) アリピプラゾールの経口医薬製剤
CN106132204A (zh) 西地那非溶液和其制备和使用方法
RU2015143993A (ru) Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением
JP4580921B2 (ja) 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む医薬組成物
EP3593819A1 (en) Compositions for therapeutic uses containing 5-htp and carbidopa
JP2016121073A (ja) 注射剤用医薬組成物の製造方法
JP2004522698A (ja) 医薬組成物のための香料系およびそのような組成物の製造方法
CN103705459A (zh) 一种结晶性头孢噻呋游离酸纳米乳注射剂及其制备方法
JP2017039694A (ja) ナルフラフィン塩酸塩含有カプセル製剤
WO2013062497A1 (en) Liquid pharmaceutical formulations
JP2007514778A5 (enExample)
JP2004099559A (ja) 医薬用ゼリー組成物
RU2778647C2 (ru) Фармацевтическая композиция в виде водного раствора, предпочтительно сиропа, содержащая инозина пранобекс и глюконат цинка, и способ ее получения
RU2649834C1 (ru) Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200317